Prostate cancer is the most common form of cancer among men in England, with cases surging by 25 per cent between 2019 and 2023, according to NHS data. It’s also the second-deadliest form of the ...

While many people are familiar with mammograms and smear tests, prostate screening is talked about far less. To shed light on this important subject ahead of Prostate Cancer Awareness Month in March, ...

THIS YEAR, IT’S estimated that nearly 300,000 new prostate cancer cases will be diagnosed. While there’s no single test to detect prostate cancer, doctors commonly use the prostate-specific antigen ...

As PSA testing recommendations change and the debate surrounding testing continues, people with a high-risk of prostate cancer and their families need to stay informed. John Salata says he is grateful ...

The prostate health index (PHI) is a blood test that more accurately assesses the risk of prostate cancer than a traditional PSA test. The PHI combines three different PSA tests to create one risk ...

To check for possible prostate cancer, physicians most often use prostate-specific antigen (PSA) tests and digital rectal exams (DREs). For a firm diagnosis, they use core needle biopsies. This page ...

Obese white men are about half as likely as normal-weight white men to have a total PSA level of 4 ng/mL or higher, a commonly used criterion for recommending a prostate biopsy, according to ...

Medicare covers one annual prostate-specific antigen (PSA) test for people with prostates if they meet the eligibility guidelines and the test is medically necessary. Medicare typically covers one ...

A new means of prostate cancer screening could emerge as an alternative to the PSA test, which has long been the first-line option. Using machine learning, a form of artificial intelligence, Swedish ...

OXFORD, England--(BUSINESS WIRE)--Oxford BioDynamics, Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests based on the EpiSwitch ® 3D genomics platform, today ...